Blue Sky BioServices, a contract research organization that provides Gene Through Screen services, secured its leadership in the market as its appoints Edward (Ted) Marple as President and CEO of the company.

"Adding Ted provides the team with a smart, energetic leader and catalyst for future scalability of customers and services," said Blue Sky's founder Paul Wengender.

"His recent leadership roles in finance, operations and strategy will be key additions to help us expand. We are excited to have him onboard as we continue to build Blue Sky as the leader in providing 'Gene Through Screen' contract research organization (CRO) services," Wengender added in a statement published in peHUB.

With this development, Mr. Wengender is expected to center his effort on the commercial endeavors of the company as he becomes its Chief Commercial Officer.

Mr. Marple takes the reign with noteworthy experience as he was the Chief Business Officer of Xcellerex, a bioprocess company that offers its services to biotech and pharmaceutical companes.